NCT06794541View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

February 17, 2029

Study Completion Date

March 19, 2029

Conditions
Complicated Intra-abdominal Infections (cIAI)
Interventions
DRUG

Eravacycline 2mg/kg

intravenous (IV) infusion

DRUG

Eravacycline 1.5mg/kg

intravenous (IV) infusion

Trial Locations (4)

26506

RECRUITING

West Virginia University Medicine Children's Hospital, Morgantown

60611

RECRUITING

Ann and Robert H Lurie Children's Hospital of Chicago, Chicago

71101

RECRUITING

Children's Hospital of LSU Health Sciences Center Shreveport, Shreveport

92868

RECRUITING

Children's Hospital of Orange County, Orange

Sponsors
All Listed Sponsors
collaborator

Innoviva Specialty Therapeutics

INDUSTRY

lead

Tetraphase Pharmaceuticals, Inc

INDUSTRY

NCT06794541 - A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI) | Biotech Hunter | Biotech Hunter